306 related articles for article (PubMed ID: 23732646)
1. Atrial selectivity of antiarrhythmic drugs.
Ravens U; Poulet C; Wettwer E; Knaut M
J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
[TBL] [Abstract][Full Text] [Related]
2. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
3. Atrial-selective K
Ravens U
Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
[TBL] [Abstract][Full Text] [Related]
4. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
[TBL] [Abstract][Full Text] [Related]
5. Revealing kinetics and state-dependent binding properties of I
Ellinwood N; Dobrev D; Morotti S; Grandi E
Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
[TBL] [Abstract][Full Text] [Related]
6. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
7. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
Aguilar-Shardonofsky M; Vigmond EJ; Nattel S; Comtois P
Biophys J; 2012 Mar; 102(5):951-60. PubMed ID: 22404917
[TBL] [Abstract][Full Text] [Related]
8. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
9. Atrial-selective sodium channel blockers: do they exist?
Burashnikov A; Antzelevitch C
J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
[TBL] [Abstract][Full Text] [Related]
10. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
Brendel J; Peukert S
Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917
[TBL] [Abstract][Full Text] [Related]
11. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
Comtois P; Sakabe M; Vigmond EJ; Munoz M; Texier A; Shiroshita-Takeshita A; Nattel S
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1489-504. PubMed ID: 18676686
[TBL] [Abstract][Full Text] [Related]
13. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria.
van Hunnik A; Nasrallah H; Lau DH; Kuiper M; Verheule S; Schotten U
Europace; 2018 Jan; 20(1):140-148. PubMed ID: 28449044
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.
Ni H; Whittaker DG; Wang W; Giles WR; Narayan SM; Zhang H
Front Physiol; 2017; 8():946. PubMed ID: 29218016
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Na
Pabel S; Ahmad S; Tirilomis P; Stehle T; Mustroph J; Knierim M; Dybkova N; Bengel P; Holzamer A; Hilker M; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Sossalla S
Basic Res Cardiol; 2020 Feb; 115(2):20. PubMed ID: 32078054
[TBL] [Abstract][Full Text] [Related]
17. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
Grunnet M; Bentzen BH; Sørensen US; Diness JG
Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches for pharmacological management of atrial fibrillation.
Ehrlich JR; Nattel S
Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation: Therapeutic potential of atrial K
Ravens U; Odening KE
Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
[TBL] [Abstract][Full Text] [Related]
20. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.
Christ T; Wettwer E; Voigt N; Hála O; Radicke S; Matschke K; Várro A; Dobrev D; Ravens U
Br J Pharmacol; 2008 Aug; 154(8):1619-30. PubMed ID: 18536759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
